Clinical trialPhase 1Recruiting
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
A Phase 1 Theranostic Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of SKL35501, an Alpha-Emitting Radiopharmaceutical Targeting NTSR1, With SKL35502 as Companion Imaging Agent in Adult Patients With Selected Advanced Solid Tumors
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Recruiting
- Study type
- Interventional
- Start
- 19 August 2026
- Expected end
- July 2030
- Enrollment
- 100 participants
- Sites
- 5
- Primary outcomes
- Number of Participants With Treatment-Emergent Adverse Events Following SKL35502 Administration; Absorbed Radiation Dose to Prespecified Normal Organs Following SKL35502 Administration; Absorbed Radiation Dose to Evaluable Tumor Lesions Following SKL35502 Administration; Whole-Body Radiation Dose Following SKL35502 Administration; Number of Participants With Dose-Limiting Toxicities During Cycle 1 Following the First Dose of SKL35501
- Sponsor
- Industry
- Results posted
- No
- Last update
- 10 September 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try